| scholarly article | Q13442814 |
| P2093 | author name string | Gary Schwartz | |
| Deborah Schrag | |||
| Leonard B Saltz | |||
| David H Ilson | |||
| William P Tew | |||
| David P Kelsen | |||
| Eileen O'Reilly | |||
| Delia Radovich | |||
| Stacey Kepler | |||
| P2860 | cites work | Cancer statistics, 2008 | Q27860585 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study | Q28364196 | ||
| Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer | Q31960280 | ||
| Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer | Q33328101 | ||
| Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. | Q33329062 | ||
| Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer | Q33341957 | ||
| Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer | Q33371032 | ||
| Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer | Q33374495 | ||
| Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer | Q33498653 | ||
| Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting | Q33499374 | ||
| Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer | Q33503431 | ||
| Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis | Q34550816 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Treatment of metastatic esophagus and gastric cancer | Q35857455 | ||
| Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer | Q39436075 | ||
| Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer | Q40800385 | ||
| Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line | Q41364890 | ||
| Effects of CPT-11 in combination with other anti-cancer agents in culture | Q41639325 | ||
| Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer | Q43850218 | ||
| Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. | Q44057365 | ||
| Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma | Q44141804 | ||
| Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer | Q44529248 | ||
| Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction | Q44908374 | ||
| CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study | Q45714364 | ||
| Esophageal Cancer | Q56209683 | ||
| Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity | Q57610374 | ||
| Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells | Q71079802 | ||
| Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus | Q72683495 | ||
| Bolus and infusional 5-fluorouracil combined with cisplatin in advanced gastric cancer | Q73081208 | ||
| A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus | Q73192094 | ||
| Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer | Q73707393 | ||
| Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors | Q77669925 | ||
| P433 | issue | 4 | |
| P921 | main subject | phase I clinical trial | Q5452194 |
| irinotecan | Q412197 | ||
| paclitaxel | Q423762 | ||
| P304 | page(s) | 366-373 | |
| P577 | publication date | 2008-10-28 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer | |
| P478 | volume | 27 |
| Q35222202 | Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress | cites work | P2860 |
Search more.